The Serine/Threonine Protein Kinase Sgk1 pipeline drugs market research report outlays comprehensive information on the Serine/Threonine Protein Kinase Sgk1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Serine/Threonine Protein Kinase Sgk1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Cardiovascular, Oncology, and Immunology which include the indications Arrhythmias, Atrial Fibrillation, Triple-Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, and Psoriasis. It also reviews key players involved in Serine/Threonine Protein Kinase Sgk1 targeted therapeutics development with respective active and dormant or discontinued products.

The Serine/Threonine Protein Kinase Sgk1 pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 1, and 2 respectively.

Serine/Threonine Protein Kinase Sgk1 overview

Serine/Threonine Protein Kinase Sgk1 is an enzyme that in humans is encoded by a gene SGK1. It plays an important role in cellular stress response. The kinase is activated by insulin and growth factors via phosphatidylinositide-3-kinase, phosphoinositide-dependent kinase PDK1 and mammalian target of rapamycin mTORC2. This kinase activates certain potassium, sodium, and chloride channels, suggesting an involvement in the regulation of processes such as cell survival, neuronal excitability, and renal sodium excretion. SGK1 expression is regulated during both discrete developmental stages and pathological conditions such as hypertension, diabetic neuropathy, ischemia, trauma, and neurodegenerative diseases. High levels of expression of this gene may contribute to conditions such as hypertension and diabetic nephropathy. It regulates several enzymes and transcription factors. SGK1 contributes to the regulation of transport, hormone release, neuro excitability, inflammation, cell proliferation and apoptosis.

For a complete picture of Serine/Threonine Protein Kinase Sgk1’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.